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ABSTRACT: Nicotine is the primary psychoactive chemical in
both traditional and electronic cigarettes (e-cigarettes). Nicotine
levels in both traditional cigarettes and e-cigarettes are an
important concern for public health. Nicotine exposure due to e-
cigarette use is of importance primarily due to the addictive
potential of nicotine, but there is also concern for nicotine
poisoning in e-cigarette users. Nicotine concentrations in e-liquids
vary widely. Additionally, there is significant genetic variability in
the rate of metabolism of nicotine due to polymorphisms of
CYP2A6, the enzyme responsible for the metabolism of
approximately 80% of nicotine. Recent studies have shown
CYP2A6 activity is also reduced by aromatic aldehydes such as
those added to e-liquids as flavoring agents, which may increase
nicotine serum concentrations. However, the impacts of flavored e-liquids on CYP2A6 activity are unknown. In this study, we
investigated the impact of three flavored e-liquids on microsomal recombinant CYP2A6. Microsomal recombinant CYP2A6 was
challenged at e-liquid concentrations ranging up to 0.125% (v/v) and monitored for metabolic activity using a probe molecule
approach. Two e-liquids exhibited dose-dependent inhibition of CYP2A6 activity. Mass spectrometry was conducted to identify
flavoring agents in flavored e-liquids that inhibited CYP2A6. Microsomal recombinant CYP2A6 was subsequently exposed to
flavoring agents at concentrations ranging from 0.03 μM to 500 μM. Cinnamaldehyde and benzaldehyde were found to be the most
potent inhibitors of microsomal CYP2A6 of the flavoring agents tested, with identified IC50 values of 1.1 μM and 3.0 μM,
respectively. These data indicate certain aromatic aldehyde flavoring agents are potent inhibitors of CYP2A6, which may reduce
nicotine metabolism in vivo. These findings indicate an urgent need to evaluate the effects of flavoring agents in e-cigarette liquids on
the pharmacokinetics of nicotine in vivo.
■ INTRODUCTION
Cytochrome P450 2A6 (CYP2A6) is one of the 60 members of
the cytochrome P450 superfamily of drug-metabolizing
enzymes found in humans.1 As is the case for other members
of the cytochrome P450 superfamily, CYP2A6 is predom-
inantly found in the liver, where it comprises approximately 4−
13% of CYP450s expressed there.2 However, CYP2A6 and its
close relative, CYP2A13, have also been identified in the
respiratory system.3,4
CYP2A6 is responsible for the metabolism of approximately
30 therapeutic molecules, including drugs such as halothane
and methoxyflurane.5 However, the enzyme is best known for
its role in nicotine oxidative metabolism.6 It is responsible for
approximately 80% of the metabolism of nicotine.7 Nicotine is
the primary psychoactive chemical of traditional and electronic
cigarettes (e-cigarettes) and is metabolized by CYP2A6 into
the intermediate metabolite nicotine-Δ 1′(5′)-iminium ion,
which is then converted to cotinine, primarily by aldehyde
oxidase (Figure 1).8
CYP2A6 is prone to inhibition by both pharmaceuticals and
environmental chemicals. Inhibitors of CYP2A6 include
methoxsalen, tranylcypromine, and a host of organosulfur
compounds.9−11 The effects of such perturbations of activity of
CYP2A6 are especially important to the metabolism of
nicotine. For example, a clinical study identified elevated
levels of nicotine blood concentrations in individuals smoking
mentholated cigarettes due to inhibition of nicotine metabo-
lism by CYP2A6 and also glucuronidation.12
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While the impact of CYP2A6 inhibition on nicotine serum
levels is known, the impact of inhibition of CYP2A6 activity
and decreased nicotine metabolism on smoking behavior and
health effects has not been fully elucidated. A 1998 study found
that individuals lacking a functioning CYP2A6 gene were less
likely to become nicotine-dependent tobacco users and on
average smoked fewer cigarettes than subjects with a fully
functional CYP2A6 gene.13 Additionally, a larger epidemio-
logic study in southern China found reduced activity CYP2A6
genotypes were associated with a lower number of cigarettes
smoked, delayed initiation of becoming a regular smoker, but
paradoxically, decreased success of smoking cessation.14 A
study involving the pharmacological inhibition of CYP2A6
found subjects given the CYP2A6 inhibitor methoxsalen
smoked fewer cigarettes and used less tobacco product, as
indicated by reduced levels of carbon monoxide.10 Conversely,
reduced CYP2A6 activity has been identified as a risk factor for
addiction in adolescents, potentially due to rapid reinforce-
ment of the psychoactive effects of nicotine.15 Additional
research is needed to elucidate the role of CYP2A6 activity on
smoking behavior.
In recent years, there has been a surge in the use of novel
tobacco products like e-cigarettes.16−19 In contrast to tradi-
tional cigarettes, e-cigarettes heat e-cigarette liquid, termed e-
liquid, using a heated coil, which then aerosolizes the e-liquid
for inhalation.20 E-liquids are primarily composed of
humectants propylene glycol (PG) and vegetable glycerin
(VG).21 However, e-liquids also contain nicotine and various
chemicals, termed flavoring agents, added to enhance the taste
of the e-liquid.22 While many of these flavoring agents are
considered safe for ingestion, their potential for toxicity when
inhaled has not been well-studied. With over 7000 e-liquid
flavors on the market, there is substantial variability in flavoring
agents used and their concentrations.23 Many of these flavoring
agents are commonly found in food and routinely ingested.24
The limited number of inhalation studies of flavoring agents
that are available indicate that while they may be safe via
ingestion, there is potential for harm when inhaled. For
instance, the flavoring agent diacetyl, used as a flavoring agent
in buttered popcorn, was found to cause bronchiolitis
obliterans syndrome when inhaled by manufacturing work-
ers.25 While many of the combustion products found in
traditional cigarette smoke are not found in e-cigarette smoke,
studies have found increased harmful aldehydes in smoke from
flavored e-liquids compared to smoke from unflavored e-
liquids.26
Limited research has been conducted on the potential for
flavored e-liquids to affect nicotine pharmacokinetics. What
little research that has been conducted suggests certain e-
liquids flavoring agents may reduce CYP2A6 activity, and
subsequently nicotine metabolism. A study on rational design
of CYP2A6 inhibitors by Tani et al. found three aromatic
aldehydes to be the most potent of CYP2A6 inhibitors
tested.27 As many e-liquid flavoring agents are aromatic
aldehydes, we believe there is potential for flavored e-liquids
to impact CYP2A6 activity. Additionally, a limited number of
aromatic aldehydes used as flavoring agents have been
investigated for effects on cytochrome P450 activity.
Cinnamaldehyde is an aromatic aldehyde commonly used as
an e-liquid flavoring agent.28 Cinnamaldehyde was found to be
an inhibitor of multiple cytochrome P450s, with CYP2A6 and
CYP2E1 being the most prone to inhibition.29 Furthermore, a
study conducted by Rahnasto et al. on benzaldehyde
derivatives found moderate to strong levels of inhibition of
CYP2A6 by the flavoring chemicals.30 However, e-liquid
flavors are oftentimes due to a complex mixture of flavoring
agents rather than just a single compound.31 Therefore, we
believe the study of potential perturbations of CYP2A6 of e-
liquids should be conducted using the e-liquid in addition to
individual flavoring agents.
While a select number of individual flavoring agents have
been screened for inhibition of CYP2A6, we were not able to
identify any existing studies that elucidate the impact of e-
liquids themselves on CYP2A6 activity. Based on flavors often
found in e-liquids, we hypothesized various e-liquids may
inhibit the enzyme CYP2A6 to varying degrees with the
potential to reduce the metabolism of nicotine. We examined
this hypothesis by testing a limited number of e-liquids using a
cell-free CYP2A6 enzyme system.
■ EXPERIMENTAL PROCEDURES
E-Liquids and Reagents. Three flavored e-liquids were
purchased from three separate vape shops. To ensure possible
variations in nicotine concentrations did not affect experiments, all
selected e-liquids were labeled by the manufacturers as nicotine-free,
which was later confirmed using gas chromatography-mass spectrom-
etry. E-liquids were selected to test dissimilar flavor profiles to
increase representativeness of e-liquids available on the marketplace.
Additionally, when possible, “best-selling” flavors were selected. The
e-liquid High Caliber Flamethrower was purchased from the online
retailer “myvaporstore.com”. Strawberry Poptart was purchased from
a local vape shop (The Vapor Girl, Chapel Hill, NC). Reds Apple
Watermelon was purchased at a separate local vape shop (Local
Liquids, Chapel Hill, NC). PG/VG ratios of selected e-liquids ranged
from 30/70 to 55/45. E-liquids were stored away from light and in
glass bottles prior to experimental use. The following flavoring
compounds were purchased from Sigma-Aldrich (St. Louis, MO):
food grade trans-cinnamaldehyde (≥95% pure), GC-grade benzalde-
hyde (≥99% pure), GC-grade isoamyl acetate (≥99% pure), GC-
grade ethyl-vanillin (≥98.5% pure), and GC-grade vanillin (≥99%
pure). A mixture of 60% PG and 40% VG obtained from
Thermofisher Scientific (Thermo Fisher Scientific, Waltham, MA)
was utilized as a vehicle control for e-liquids.
Preparation of E-Liquids and Flavoring Agents. 1.25% (v/v)
stock solutions of e-liquids were prepared in Thermo Fisher Vivid
reaction buffer II prior to experimental use. Working solutions were
diluted in 0.5× Vivid reaction buffer II. Because test compounds are
diluted with other reagents upon addition to a well, test compounds
are prepared at 2.5× screening concentration using 0.5× Vivid
reaction buffer II. E-liquids were screened for CYP2A6 inhibition at
seven separate concentrations ranging up to 0.125% (v/v) using a 4-
fold serial dilution scheme. 2.5 mM stock solutions of individual
flavoring agents were prepared in Thermo Fisher Vivid reaction buffer
II. Flavoring agents identified in e-liquids using mass spectrometry
and two other common e-liquid flavoring agents were screened for
CYP2A6 inhibition at concentrations up to 500 μM using a 4-fold
serial dilution scheme.
Figure 1. Primary nicotine metabolic pathway. Nicotine is
metabolized by CYP2A6 and aldehyde oxidase to form cotinine.
Nicotine initially undergoes metabolic oxidation by CYP2A6 to form
the intermediate metabolite nicotine-Δ 1′(5′)-iminium ion, which is
in equilibrium with 5′-hydroxynicotine. The intermediate metabolite
is then metabolized by aldehyde oxidase to cotinine.
Mass Spectrometry. Qualitative mass spectrometry was con-
ducted on e-liquids to identify flavoring agents in e-liquids and vehicle
control using gas chromatography-mass spectrometry (GC-MS).
Qualitative e-liquid analysis was performed on a Bruker EVOQ 456
gas chromatograph-triple quadrupole mass spectrometer using an
Agilent DB-5MS capillary column (30 m, 0.25 mm ID, 0.25 μM film)
and helium carrier gas. Injections of 1 μL were performed using a
Bruker CP-8400 autosampler with an injector temperature of 270 °C
and a split ratio of 50:1. The GC oven was programmed with a 12.5
min temperature gradient (60−250 °C), and the transfer line and
electron ionization source were held at 250 °C. Samples were
prepared by diluting 10 μL of e-liquid in 1 mL of methanol (optima
grade) and vortexing for 30 s. Full-scan mass spectra were acquired
from m/z 40−500. Compound identification was performed using the
NIST 2014 mass spectral database and Bruker MS Data Review
software.
For Flamethrower and Strawberry Poptart, quantitative MS was
conducted to quantify flavoring agents using the same instrument
conditions utilized for qualitative mass spectrometry. Concentrations
were determined by standard addition. E-liquids were diluted in
methanol (optima grade) with quantitative standards. Full-scan mass
spectra were acquired using the same instrument method mentioned
previously. Peak areas of cinnamaldehyde, vanillin, and ethyl vanillin
were integrated for quantification.
Microsomal Recombinant Human Cytochrome P450 2A6
Activity Screening. Vivid recombinant human cytochrome P450
2A6 microsomes, Vivid microsomal recombinant human cytochrome
b5, NADP+, 3-cyanocoumarin, 3-cyano 7-hydroxycoumarin, and
Vivid regeneration system consisting of glucose-6-phosphate and
glucose-6-phosphate dehydrogenase were obtained from Thermo-
fisher Scientific (Waltham, MA). trans-2-Phenylcyclopropylamine
hydrochloride (tranylcypromine) was purchased from Sigma
(Sigma-Aldrich, St. Louis, MO).
To screen e-liquids and flavoring agents for inhibition of CYP2A6,
ThermoFisher Scientific Vivid fluorescence-based CYP2A6 inhibition
screening kits were utilized at room temperature, minimizing
volatilization of e-liquid flavoring agents. Assays were carried out in
Costar medium binding 96-well black polystyrene plates (Fisher
Scientific, Waltham, MA). Tranylcypromine, a potent CYP2A6
inhibitor, was utilized as positive control at 100 μM. Vivid
regeneration system and Vivid microsomal recombinant CYP2A6
Baculosomes at 10 nM were dispensed to each well containing test
chemical for an incubation time of 10 min. After 10 min incubation,
the nonfluorescent CYP2A6 substrate 3-cyanocoumarin and NADP+
were added to each well at 10 μM and 30 μM, respectively. CYP2A6
activity was monitored by measuring the production of fluorescence
produced by the metabolism of 3-cyanocoumarin into 3-cyano-7-
hydroxycoumarin, its fluorescent metabolite, using a BMG LabTech
CLARIOstar microplate reader (Cary, NC). Fluorescence due to of 3-
cyano-7-hydroxycoumarin was measured in kinetic mode every
minute for 60 min at excitation λ = 415, emission λ = 460.
Statistical Analyses. Data were generated from experiments
conducted on three separate days and were performed in duplicate
each day. E-liquid dilutions were formed immediately prior to
experiment each day. When appropriate, data were compared to PG/
VG vehicle control and positive inhibition control (100 μM
tranylcypromine). Fluorescence in the presence of 100 μM
tranylcypromine is considered the maximal percent inhibition for
microsomal recombinant CYP2A6. Fluorescence for each well was

















where A is the relative fluorescence units observed in the presence of
the test compound, B is the relative fluorescence units observed in the
presence of known CYP2A6 inhibitor (100 μM tranylcypromine), and
C is the relative fluorescence units observed in the PG/VG vehicle
control. All fluorescence values used in eq 1 are at 60 min incubation
time.
Statistical analyses were conducted using GraphPad Software Inc.
Prism 8.0.1 (San Diego, CA). Results are expressed as means ±
standard error of the mean (SEM) collected from six individual
replicates. Unless otherwise stated, statistical significance is
determined as results having a p-value of <0.05. The p-values are
calculated in GraphPad Prism 8.0.1 using a two-way analysis of
variance with Dunnett’s multiple comparisons test to compare case
samples to appropriate controls.
The half maximal inhibitory concentration (IC50) of CYP2A6 was
calculated for each e-liquid and individual flavoring agent. The 95%
confidence intervals of IC50 values are listed after each calculated IC50.
IC50 values for each e-liquid and flavoring agent were calculated using
a four-parameter variable slope function in GraphPad Prism 8.0.1.
■ RESULTS
Certain Flavored E-Liquids Inhibit Microsomal Re-
combinant CYP2A6 Activity. To determine whether e-
liquids and e-liquid flavoring agents perturb the activity of
CYP2A6, we exposed microsomal recombinant CYP2A6 to
PG/VG (vehicle control) or e-liquids in a 96-well plate format
and monitored the production of 3-cyano 7-hydroxycoumarin,
the fluorescent metabolite of 3-cyanocoumarin. The vehicle
control, 60/40 PG/VG, at 0.125% (v/v) did not impact the
activity of microsomal recombinant CYP2A6 (Figure 2). In
contrast, at 0.125% (v/v), the highest concentration tested,
Apple Watermelon exhibited an average CYP2A6 inhibition of
25.8% relative to maximal inhibition identified utilizing 100
μM tranylcypromine. As illustrated in Figure 3, lower
concentrations of Apple Watermelon exhibited negligible
microsomal recombinant CYP2A6 inhibition. Strawberry
Poptart exhibited near maximal inhibition of CYP2A6 at
0.125% and 0.031% (v/v) and exhibited an average inhibition
of 61.5% and 22.7% of microsomal recombinant CYP2A6 at
0.0078% and 0.0019%, respectively. Flamethrower exhibited
the most potent inhibition of microsomal recombinant
CYP2A6. Near-complete inhibition of microsomal recombi-
nant CYP2A6 was identified down to 0.0078% (v/v).
Flamethrower exhibited microsomal recombinant CYP2A6
inhibition of 79.8%, 54.7%, and 22.7% of maximal inhibition at
0.0019% (v/v), 0.00048% (v/v), and 0.00012% (v/v),
respectively (Figure 3).
Additional control experiments were conducted to ensure
dose-dependent decrease in fluorescence observed by e-liquid
incubation was due to inhibition of microsomal recombinant
CYP2A6 rather than a non-inhibitory mechanism or
perturbation in assay conditions. To ensure pH of assay
Figure 2. PG/VG effect on microsomal recombinant CYP2A6
activity. 0.125% (v/v) PG/VG (vehicle control) did not significantly
decrease activity of microsomal recombinant CYP2A6 at 60 min
incubation time relative to negative control; n = 3, mean ± SEM.
Ratio paired t test identified no significant differences in fluorescence
by 0.125%(v/v) PG/VG.
conditions was not altered by e-liquid flavoring agents, the pH
of 0.125% (v/v) e-liquid in 0.5× Vivid buffer II was measured
for each e-liquid. Alterations of the pH of 0.5× Vivid buffer II
was determined to not have been adversely affected by the
presence of any e-liquid at 0.125% (v/v). Background
fluorescence was also measured for each e-liquid and was
determined to have a negligible effect for each e-liquid (data
not shown).
To ensure reduced presence of the fluorescent metabolite by
Flamethrower and Strawberry Poptart was due to microsomal
recombinant CYP2A6 inhibition and not due to flavoring agent
interaction with the metabolite, we incubated the fluorescent
metabolite, 3-cyano 7-hydroxycoumarin, at 0.5 μM in 0.5% (v/
v) of each e-liquid for 60 min at room temperature. There was
no significant decrease of fluorescence of the metabolite by
either Flamethrower or Strawberry Poptart. This indicates that
flavored e-liquids and flavoring agents do not interact with 3-
cyano 7-hydroxycoumarin to reduce fluorescence at the
designated wavelength (data not shown).
The IC50 was calculated using the seven concentrations
tested. As seen in Table 1, due to insufficient microsomal
recombinant CYP2A6 inhibition, an IC50 was not calculable for
Apple Watermelon. The IC50 of Strawberry Poptart and
Flamethrower were calculated as 0.0058% (v/v) (0.0048%,
0.0069%), and 0.00038% (v/v) (0.00025%, 0.00052%),
respectively. IC50 values are summarized in Table 1.
Qualitative Mass Spectrometry. The primary objective
of conducting qualitative mass spectrometry on the selected
flavored e-liquids was to identify specific flavoring agents
within each liquid that may be responsible for inhibition of
microsomal recombinant CYP2A6. The e-liquids were
analyzed in nontargeted scan mode. If listed below, each
identified flavoring agent was confirmed using Agilent GC-MS
National Institute of Standards and Technology (NIST) mass
spectral library. Retention time as well as R-match scores,
based on retention time and mass spectral patterns, are also
listed for each identified flavoring agent. Chromatograms are
shown in Figure 4A−D. As expected, PG (1.8 min) and VG
(4.3 min) were detected in all e-liquids, including the vehicle
control. Apple Watermelon also contained triglyceride 1,2,3-
triacetoxypopane (6.7 min, R-match: 850), commonly known
as triacetin (Figure 4B). Triacetin is a humectant and flavoring
agent commonly found in e-liquids.32 Strawberry Poptart
contained triacetin (6.7 min, R-match: 873), vanillin (7.2 min,
R-match: 896), and ethyl vanillin (7.6 min, R-match: 877)
(Figure 4C). Additional peaks were visible in the Strawberry
Poptart chromatogram but were not identifiable with high
confidence using the NIST library without the use of analytical
standards. The most plausible matches for the peaks are benzyl
alcohol (4.3 min) and acetaldehyde (5.9 min). Flamethrower
contained cinnamaldehyde (6.4 min, R-match: 929) (Figure
4D). Additional peaks were visible in the Flamethrower
chromatogram but were not identifiable with high confidence
using the NIST library without the use of analytical standards.
The most plausible matches for the peaks at 8.4 and 9.9 min
are cinnamyl alcohols. trans-Cinnamaldehyde had some
matching; however, the trans-cinnamaldehyde analytical stand-
ard eluted considerably earlier than 8.4 min, and the mass
spectra of the two unidentified peaks at 8.4 and 9.9 min did not
resemble the mass spectra of the trans-cinnamaldehyde
Figure 3. E-liquid inhibition of microsomal recombinant CYP2A6 at 60 min. E-liquids were screened for CYP2A6 inhibition at concentrations
ranging from 0.000031% to 0.125% (v/v). Flamethrower exhibited an inhibition of microsomal recombinant CYP2A6 at concentrations as low as
0.00012%, while Strawberry Poptart exhibited an inhibition of microsomal recombinant CYP2A6 at 0.0019% (v/v). Apple Watermelon exhibited
only limited inhibition at 0.125% (v/v). Percent inhibition calculated from the PG/VG baseline. Mean ± SEM, n = 3.
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IC50 of 3-cyano coumarin 7-
hydroxylation (%)








0.000031 0.125 Flamethrower 0.00038 0.00025−0.00052
aFor screening of e-liquids impact on microsomal recombinant CYP2A6 activity, each concentration was screened on three separate days in
duplicate (n = 3).
Figure 4. Chromatograms of PG/VG (vehicle control) and selected flavored e-liquids. (A) PG/VG vehicle control chromatogram peaks were
identified as PG (1.8 min) and VG (4.3 min). (B) Apple Watermelon chromatogram flavoring agent peak was identified as triacetin (6.7 min). (C)
Strawberry Poptart chromatogram flavoring agent peaks were identified as triacetin (6.7 min), vanillin (7.2 min), and ethyl vanillin (7.6 min). (D)
Flamethrower chromatogram flavoring agent peak was identified as and trans-cinnamaldehyde (6.4 min).
Figure 5. E-liquid flavoring agent inhibition of microsomal recombinant CYP2A6. Cinnamaldehyde and benzaldehyde exhibited the strongest dose-
dependent inhibition of microsomal recombinant CYP2A6. Vanillin and ethyl vanillin exhibited a less potent inhibition of microsomal recombinant
CYP2A6. Isoamyl acetate exhibited no inhibition at even the highest concentration. Each concentration was screened on three separate days in
duplicate (n = 3). Mean ± SEM.
standard. Furthermore, R-match scores for the two unidenti-
fied peaks were higher for a cinnamyl alcohol than trans-
cinnamaldehyde. Therefore, we believe the unidentified peaks
are more likely a cinnamyl alcohol. Qualitative mass
spectrometry was also conducted to ensure no nicotine was
present in e-liquids labeled as nicotine-free.
Certain E-Liquid Flavoring Agents Inhibit Microsomal
Recombinant CYP2A6 Activity. To examine what specific
flavoring agents may impact microsomal recombinant CYP2A6
activity, and thereby potentially affecting the metabolism of
nicotine in e-cigarette users, we subsequently screened the
three flavoring agents identified using qualitative mass
spectrometry in e-liquids that inhibited microsomal recombi-
nant CYP2A6. In addition to cinnamaldehyde, vanillin, and
ethyl vanillin, two other flavoring agents that are commonly
found in e-liquids, benzaldehyde and isoamyl acetate, were
screened for inhibition of microsomal recombinant
CYP2A6.33−35 Isoamyl acetate, the only non-aldehyde
screened for impacts to microsomal recombinant CYP2A6
activity, was selected for comparison. E-liquid flavoring agents
were screened for inhibition of CYP2A6 at eight concen-
trations ranging from 0.03 μM to 500 μM. As triacetin was
present in an e-liquid (Apple Watermelon) that had a
negligible effect on microsomal recombinant CYP2A6 activity,
it was not screened for inhibition of microsomal recombinant
CYP2A6 activity.
The e-liquid flavoring agents were screened using the same
assay conditions as e-liquids. Because flavoring agents were
dissolved directly into Vivid reaction buffer II prior to
experimental use, no vehicle control was necessary. The
fluorescence intensity in the absence of an inhibitor or test
chemical was treated as the maximal microsomal recombinant
CYP2A6-mediated 3-cyano-7-hydroxycoumarin formation. As
the data in Figure 5 illustrate, benzaldehyde and cinnamalde-
hyde were the most potent inhibitors of microsomal
recombinant CYP2A6. Both benzaldehyde and cinnamalde-
hyde exhibited a strong dose-dependent microsomal recombi-
nant CYP2A6 inhibition. An IC50 value of 1.1 μM (0.65 μM,
1.67 μM) was identified for cinnamaldehyde, indicating
cinnamaldehyde is a potent inhibitor of microsomal recombi-
nant CYP2A6. Benzaldehyde also appeared to be a potent
inhibitor of microsomal recombinant CYP2A6, with an IC50 of
3.0 μM (1.56 μM, 5.37 μM). The two heavier aromatic
aldehydes, vanillin and ethyl vanillin, exhibited significantly
lower potency for microsomal recombinant CYP2A6 inhib-
ition. Vanillin and ethyl vanillin exhibited a nearly identical
dose−response curve, with near-maximal inhibition occurring
only at 500 μM. The calculated IC50 values for vanillin and
ethyl vanillin were 70.0 μM (46.5 μM, 164 μM) and 69.4 μM
(57.0 μM, 89.3 μM), respectively. Isoamyl acetate, the sole
non-aldehyde tested, exhibited negligible inhibition of micro-
somal recombinant CYP2A6 up to 500 μM, suggesting that
aromatic aldehydes may be more apt to inhibit microsomal
recombinant CYP2A6. Due to limited inhibition of microsomal
recombinant CYP2A6, an IC50 was not calculable for isoamyl
acetate. IC50 values of flavoring agents are summarized in
Table 2.
Quantitative Mass Spectrometry. Quantitative GC-MS
analysis was used to identify the concentration of cinnamalde-
hyde in Flamethrower as well as the concentration of vanillin
and ethyl vanillin in Strawberry Poptart. GC-MS revealed a
cinnamaldehyde concentration of 295.3 mM in Flamethrower.
Vanillin in Strawberry Poptart was detected at 26.4 mM, while
ethyl vanillin was found at 7.3 mM.
■ DISCUSSION
In the present study, purified microsomal recombinant
CYP2A6 was used to evaluate the potential for e-liquids and
common e-liquid flavoring agents to inhibit CYP2A6, the
enzyme that metabolizes approximately 80% of nicotine in the
body. Reduced activity of CYP2A6, whether reduced function
genotype or pharmacological inhibition, has been shown to
alter serum concentrations of nicotine.36,37 The data presented
here indicate certain e-liquids, and common flavoring agents of
e-liquids are capable of inhibiting microsomal recombinant
CYP2A6, which may impact nicotine metabolism in vivo.
As flavored e-liquids are a complex mixture of chemicals, it
was revealing to test the impact of the e-liquid as a whole
rather than relying on findings of individual flavoring agents. A
mixture may cause an effect that is notably different than the
sum of effects of individual chemicals that comprise the
mixture. The primary concern is that certain chemicals within
the mixture may reduce or enhance the effect of other
chemicals within the mixture, termed a cocktail effect.
To determine whether the primary flavoring agents are
responsible for the inhibition of CYP2A6 by the flavored e-
liquids, we utilized the quantitative mass spectrometry results
of cinnamaldehyde in Flamethrower and the vanillin and ethyl
vanillin levels in Strawberry Poptart. As illustrated in Table 3,
we calculated what we would expect the IC50 to be for
Flamethrower based on the measured IC50 of 1.1 μM identified
for cinnamaldehyde in the microsomal recombinant CYP2A6




tested (μM) flavoring agent
IC50 of 3-cyano coumarin 7-
hydroxylation (μM)
IC50 95% confidence interval (lower limit−
upper limit, μM)
0.03 500 isoamyl acetate >500 −
0.03 500 vanillin 70.0 46.5−164
0.03 500 ethyl vanillin 69.4 57.0−89.3
0.03 500 benzaldehyde 3.0 1.6−5.5
0.03 500 cinnamaldehyde 1.1 0.65−1.7





measured IC50 of primary
flavoring agent (μM)
Concentration of flavoring
agent in e-liquid (mM)
expected IC50 of e-liquid based on
flavoring IC50 and concentration (%)
identified IC50 of
e-liquid (%)





ethyl vanillin 69.4 7.3
assay and the measured concentration of cinnamaldehyde in
Flamethrower. Based on the measured cinnamaldehyde IC50
and the cinnamaldehyde concentration in Flamethrower of 295
mM, we would expect an IC50 of 0.00037% (v/v) for the e-
liquid. This value is nearly identical to the measured IC50 value
of 0.00038% (v/v) for Flamethrower. As illustrated in the
microsomal recombinant CYP2A6 assay, this finding indicates
the inhibition of CYP2A6 by Flamethrower is likely
predominantly driven by the presence of cinnamaldehyde.
To determine whether vanillin and ethyl vanillin were the
flavoring agents primarily responsible for inhibiting micro-
somal recombinant CYP2A6 additively, we calculated what we
would expect the IC50 for Strawberry Poptart to be based on
the measured vanillin concentration of 26.4 mM and ethyl
vanillin concentration of 7.3 mM, in conjunction with
measured IC50 of 70 μM and of 69.4 μM, respectively. Based
on the concentration and measured IC50 of the two primary
flavoring agents, we would expect an IC50 of CYP2A6 for
Strawberry Poptart to be 0.21% (v/v) if the chemicals acted on
CYP2A6 additively (Table 3). This is markedly higher than the
measured IC50 of 0.0058% (v/v) for Strawberry Poptart for
microsomal recombinant CYP2A6. While additional experi-
ments are necessary to identify the cause of the difference in
potency, it is possible the chemicals that formed the
unidentified peaks in the qualitative mass spectrometry
chromatogram may also exhibit an inhibitory effect on
microsomal recombinant CYP2A6. Additionally, the possibility
of a synergistic effect on CYP2A6 inhibition between the
chemicals must be investigated.
While we tested only a small fraction of e-liquids currently
on the marketplace for inhibition of microsomal recombinant
CYP2A6 activity, we believe our findings from five common e-
liquid flavoring agents are relevant to a broad portion of e-
liquids currently available on the market. All four of the
flavoring agents that exhibited some extent of inhibition of
microsomal recombinant CYP2A6 were aromatic aldehydes.
The only non-aromatic aldehyde tested was isoamyl acetate,
which had no impact on the activity of CYP2A6. While the
number of e-liquids and flavoring agents screened in the
present study was limited, CYP2A6 appears to be prone to
inhibition by aromatic aldehydes. The mechanism of CYP2A6
inhibition by aromatic aldehydes is not known. However,
interaction with a cysteine or lysine residue has been suggested
as a possible mechanism of inhibition.29 The two lower
molecular weight aldehydes, benzaldehyde (MW: 106.12) and
cinnamaldehyde (MW: 132.16), were the more potent of the
aromatic aldehydes for CYP2A6 inhibition. The two vanillin
derivatives, vanillin (MW: 152.15) and ethyl vanillin (MW:
166.16), were less potent than benzaldehyde and cinnamalde-
hyde.
The question of biological relevance is inherently important
when interpreting results from an isolated enzyme system. E-
liquid flavoring agents will be delivered concomitantly with
nicotine via inhalation. Because CYP2A6, like the vast majority
of cytochrome P450s, is predominantly found in the liver, e-
liquid flavoring agents must first be readily absorbed into the
bloodstream in order to interact with hepatic CYP2A6. While
nicotine in e-cigarettes is readily absorbed through epithelial
cells and into the bloodstream, there is limited information on
the deposition, absorption, and distribution of the various e-
liquid flavoring agents when inhaled as well as limited data on
the amount and site of deposition of e-cigarette aerosols
particles in general.
Due to the limited data on absorption and distribution of the
tested flavoring agents via inhalation, it is not currently feasible
to determine what effect the inhalation of such flavored e-
liquids may have on activity of hepatic CYP2A6 in vivo. Since
many e-liquid flavoring agents are routinely ingested via diet,
an argument has been made that the inhalation of such
flavoring agents is unlikely to have a stronger impact on
CYP2A6 activity than orally administered flavoring agents.
However, e-cigarette aerosols are rapidly delivered to the
respiratory tract when inhaled, and bioavailability may be
altered when flavoring agents are inhaled as compared to
ingested. Therefore, it is not appropriate to compare exposure
of aromatic aldehydes via ingestion to exposure to aromatic
aldehydes via inhalation. Additional research is necessary to
determine the absorption of various e-liquid flavoring agents to
the bloodstream in order to determine whether inhibition of
CYP2A6 in vivo may impact nicotine metabolism.
■ CONCLUSIONS
The data presented here indicate certain e-liquids and a subset
of common e-liquid flavoring agents inhibit microsomal
recombinant CYP2A6 to varying degrees. While only
preliminary, these findings may be relevant to current and
emerging concerns regarding health impacts of nicotine in e-
cigarettes as well as the impact of flavorings on nicotine
pharmacokinetics. This study highlights the need for
investigation of the possible synergistic effect of chemicals in
e-liquids on CYP2A6 inhibition, confirmation of the micro-
somal recombinant CYP2A6 finding in a cell-based system, as
well as the need for additional research on absorption of e-
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